All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the latest advances in treating high-risk smoldering myeloma?

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Mark Bustoros, Dana-Farber Cancer Institute, Boston, US, answers the question: What are the latest advances in treating high-risk smoldering myeloma?

Dr Bustoros presents the results from a phase II trial of ixazomib, lenalidomide and dexamethasone in patients with high-risk smoldering myeloma. 48/53 patients were evaluable for response, with nearly 50% achieving a complete response (CR) or very good partial response (VGPR). 70% of patients who achieved CR were also minimal residual disease (MRD) negative. It was also a well-tolerated regimen, administered orally.

What are the latest advances in treating high-risk smoldering myeloma?

Share: